Matches in SemOpenAlex for { <https://semopenalex.org/work/W2536698082> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2536698082 abstract "Objective: A post-hoc subgroup analysis of data from a Phase III trial was conducted to investigate the efficacy of rufinamide in adults with Lennox Gastaut Syndrome (LGS).Background: Rufinamide is a triazole derivative, structurally unrelated to other antiepileptic drugs, approved for adjunctive treatment of seizures associated with LGS in patients aged ≥1 years. LGS often persists into adulthood, or may have late-onset in adulthood.1 Management of LGS in adulthood is challenging; seizures are often intractable and most patients have moderate to severe cognitive impairment.1Design/Methods: A randomized, double-blind, placebo-controlled trial was conducted in patients with LGS, aged 437 years, with history of multiple seizures types (including tonic-atonic and atypical absence seizures) and a minimum of 90 seizures prior to the 28-day Baseline period. During a 14-day Titration phase plus 70-day Maintenance period, patients received double-blind treatment with either rufinamide (titrated to ~45 mg/kg/day maximum) or placebo. Efficacy in adult patients (≥18 years) was assessed as median percentage change from baseline per 28 days of all seizures and tonic-atonic seizures during double-blind treatment.Results: Adults with LGS were randomized to adjunctive treatment with rufinamide (n=21; 15 Male, 6 Female) or placebo (n=10; 5M, 5F). Mean (standard deviation [SD]; range) age was 25.2 (4.7; 1835) and 29.3 (7.1; 1837) years in the rufinamide and placebo groups, respectively; mean (SD; range) time since LGS diagnosis was 18.5 (8.9; 033) and 25.5 (8.1; 834) years, respectively. Median change from baseline in seizure frequency was -31.5[percnt] for rufinamide versus +22.1[percnt] for placebo (p=0.008, Wilcoxon Rank-Sum test, unadjusted) for all seizures and -54.9[percnt] versus +21.7[percnt] (p=0.002), respectively, for tonic-atonic seizures.Conclusions: Rufinamide demonstrated favourable efficacy, compared with placebo, when used as adjunctive treatment for adults with LGS.Ref: 1Arzimanoglou et al. Lancet.2009;8(1):82-93.Support: Eisai Inc. Disclosure: Dr. Striano has received personal compensation for activities with Shire Pharma and Eisai Inc. Dr. McMurray has received personal compensation for activities with Eisai Ltd. as an employee." @default.
- W2536698082 created "2016-10-28" @default.
- W2536698082 creator A5028296509 @default.
- W2536698082 creator A5088309302 @default.
- W2536698082 date "2016-04-05" @default.
- W2536698082 modified "2023-09-23" @default.
- W2536698082 title "Efficacy of Rufinamide as Adjunctive Treatment for Adults With Lennox-Gastaut Syndrome: Subgroup Analysis From a Phase III Trial (P2.056)" @default.
- W2536698082 hasPublicationYear "2016" @default.
- W2536698082 type Work @default.
- W2536698082 sameAs 2536698082 @default.
- W2536698082 citedByCount "0" @default.
- W2536698082 crossrefType "journal-article" @default.
- W2536698082 hasAuthorship W2536698082A5028296509 @default.
- W2536698082 hasAuthorship W2536698082A5088309302 @default.
- W2536698082 hasConcept C118552586 @default.
- W2536698082 hasConcept C126322002 @default.
- W2536698082 hasConcept C141071460 @default.
- W2536698082 hasConcept C142724271 @default.
- W2536698082 hasConcept C168563851 @default.
- W2536698082 hasConcept C187212893 @default.
- W2536698082 hasConcept C187960798 @default.
- W2536698082 hasConcept C204787440 @default.
- W2536698082 hasConcept C27081682 @default.
- W2536698082 hasConcept C2778186239 @default.
- W2536698082 hasConcept C2779307984 @default.
- W2536698082 hasConcept C3018162438 @default.
- W2536698082 hasConcept C42219234 @default.
- W2536698082 hasConcept C44249647 @default.
- W2536698082 hasConcept C71924100 @default.
- W2536698082 hasConceptScore W2536698082C118552586 @default.
- W2536698082 hasConceptScore W2536698082C126322002 @default.
- W2536698082 hasConceptScore W2536698082C141071460 @default.
- W2536698082 hasConceptScore W2536698082C142724271 @default.
- W2536698082 hasConceptScore W2536698082C168563851 @default.
- W2536698082 hasConceptScore W2536698082C187212893 @default.
- W2536698082 hasConceptScore W2536698082C187960798 @default.
- W2536698082 hasConceptScore W2536698082C204787440 @default.
- W2536698082 hasConceptScore W2536698082C27081682 @default.
- W2536698082 hasConceptScore W2536698082C2778186239 @default.
- W2536698082 hasConceptScore W2536698082C2779307984 @default.
- W2536698082 hasConceptScore W2536698082C3018162438 @default.
- W2536698082 hasConceptScore W2536698082C42219234 @default.
- W2536698082 hasConceptScore W2536698082C44249647 @default.
- W2536698082 hasConceptScore W2536698082C71924100 @default.
- W2536698082 hasLocation W25366980821 @default.
- W2536698082 hasOpenAccess W2536698082 @default.
- W2536698082 hasPrimaryLocation W25366980821 @default.
- W2536698082 hasRelatedWork W1551373999 @default.
- W2536698082 hasRelatedWork W1607760171 @default.
- W2536698082 hasRelatedWork W1799393019 @default.
- W2536698082 hasRelatedWork W2000153988 @default.
- W2536698082 hasRelatedWork W2042952537 @default.
- W2536698082 hasRelatedWork W2061457158 @default.
- W2536698082 hasRelatedWork W2169966598 @default.
- W2536698082 hasRelatedWork W2239952012 @default.
- W2536698082 hasRelatedWork W2383659930 @default.
- W2536698082 hasRelatedWork W2578790984 @default.
- W2536698082 hasRelatedWork W2809077394 @default.
- W2536698082 hasRelatedWork W2885635596 @default.
- W2536698082 hasRelatedWork W2889534309 @default.
- W2536698082 hasRelatedWork W2889968052 @default.
- W2536698082 hasRelatedWork W2914333425 @default.
- W2536698082 hasRelatedWork W2925073929 @default.
- W2536698082 hasRelatedWork W2995607922 @default.
- W2536698082 hasRelatedWork W2998806808 @default.
- W2536698082 hasRelatedWork W3159562706 @default.
- W2536698082 hasRelatedWork W3183596813 @default.
- W2536698082 hasVolume "86" @default.
- W2536698082 isParatext "false" @default.
- W2536698082 isRetracted "false" @default.
- W2536698082 magId "2536698082" @default.
- W2536698082 workType "article" @default.